The oligonucleotide ligation assay (OLA) has been proposed as an affordable alternative to sequence-based HIV-1 drug resistance testing in resource poor settings.
The dramatic reduction in the cost of sequencing has made bacterial genome sequencing affordable to a great number of labs, leading to a democratization of sequencing (Shendure and Ji 2008).
(When the company debuted its service in late 2007, it cost $350,000). That means that within the next few years, having your genome sequenced will cost about the same as cataract surgery, making it affordable to include your genome sequence as an integral part of your medical record.
When it becomes affordable to have one's genome sequenced, perhaps in a few years, a longevity test, though not a foolproof one, may be feasible, if a new claim holds up.
Today, it's possible — and even affordable — to have your entire genome sequenced, says Dr. Gianrico Farrugia, director of the Center for Individualized Medicine at the Mayo Clinic in Rochester, Minn.
As the cost of NGS decreases, instead of sequencing DNA samples from a subset of family members, an affordable strategy will be to sequence all available pedigree members.
The rapidly decreasing costs of sequencing make these technologies affordable to small and medium size laboratories.
Current sequencing technologies have become affordable to be used in routine microbial identification [ 9, 10].
For example, the ability to sequence genomes at an affordable cost, and the ability to measure complete transcriptomes using RNA sequencing.
Indeed, there is every reason to believe that the pace of discovery will continue to accelerate as sequencing costs fall and exome sequencing gives way to affordable whole-genome sequencing, allowing examination for the first time of non-coding and regulatory regions of DNA and their potential contributions to disease.
